Market Access News | pharmaphorum

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

Ipsen drug is first therapy for rare bone disease FOP in US

With FDA approval, Ipsen's marathon effort to bring palovarotene to market for the rare disease fibrodysplasia ossificans progressiva (FOP) has finally crossed the finish

News

FDA starts speedy review of Servier's Tibsovo in MDS

Servier could become the first company to bring an IDH inhibitor to market in the US for patients with myelodysplastic syndromes (MDS) next year, after the FDA started a p

News

Four digital weight-loss programmes get NICE support

People seeking help from the NHS to lose weight may soon be eligible to use digital programmes delivered via a smartphone or computer.

News

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least

News

AI can be used to speed up radiotherapy planning, says NICE

Draft guidance from NICE has recommended that nine artificial intelligence technologies can be used by NHS England to help plan the treatment of those undergoing external

Keytruda backed for 'basket' of new cancers via NHS

Ipsen drug is first therapy for rare bone disease FOP in US

FDA starts speedy review of Servier's Tibsovo in MDS

Four digital weight-loss programmes get NICE support

Pfizer joins off-the-shelf BCMA fight with Elrexfio okay

AI can be used to speed up radiotherapy planning, says NICE

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks